Lightstone Ventures
Edit

Lightstone Ventures

https://www.lightstonevc.com
Last activity: 08.01.2025
Active
Invests in categories: MedtechHardwareHealthTechDevelopmentTechnologyDrugProductBioTechCareHuman
News
361
Portfolio
58
Mentions
31
Employees: 11-50
Investment Type: Venture Capital
.

Portfolio 58

DateNameWebsiteTotal RaisedLocation
10.06.2022Ligature T...ligaturetx.com$6MSingapore
07.04.2022Cardiac Bo...cardiacbooster.com-Netherland...
06.04.2022404 Errormedisixtx.com-Singapore
05.03.2022Contego Me...contegomedical.com$43.3MUnited Sta...
02.03.2022The Foundr...thefoundry.com-United Sta...
18.01.2022ProVerumproverummedical.com-Ireland, D...
21.12.2021Trotana, I...trotana.com-United Sta...
20.08.2021Vigil Neur...vigilneuro.com$215MUnited Sta...
14.05.2021Allay Ther...allaytx.com$60MUnited Sta...
22.04.2021Alchemab T...alchemab.com$82.59MUnited Kin...
Show more

News 361

DateTitleDescription
11.11.2022Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting-
28.10.2022And the best medical device innovation of 2022 goes to…-
26.10.2022Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer-
16.10.2022Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activators of AMPK-
14.09.2022ClavystBio launches to translate life sciences breakthroughs into health impact-
16.08.2022Vigil Neuroscience Announces $75 Million Private Placement Financing-
12.08.2022Gemini Therapeutics and Disc Medicine Announce Merger Agreement-
12.08.2022Merck is back in Alzheimer’s saddle with $1B+ Cerevance pact, years after dropping the BACE-
28.07.2022Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D.-
28.07.2022Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors-
Show more

Mentions in press and media 31

DateTitleDescription
08.01.2025FIRE1 Secures $120M for Heart Failure Management PlatformWhat You Should Know: – FIRE1, a connected medical device company, announced it has secured $120M in funding to advance its mission to transform the lives of millions of people living with heart failure. The round was led by Polaris Partner...
23.02.2024Reprieve Cardiovascular Revolutionizes Heart Failure Treatment with $42M FundingReprieve Cardiovascular, a Milford, MA-based company, secures $42M in Series A funding to advance intelligent fluid management for heart failure patients. Led by Lightstone Ventures and Sante Ventures, the funding will propel Reprieve's mis...
22.02.2024Reprieve Cardiovascular Nabs $42M to Expand Intelligent Fluid Management for Heart FailureWhat You Should Know: – Reprieve Cardiovascular, a pioneer in personalized fluid management for acute decompensated heart failure (ADHF) emerges from stealth launching with $42M in Series A financing round. – The Series A round was co-led b...
26.06.2023Dutch-based Tagworks Pharmaceuticals raises €59.5M to design effective, safe systemic therapiesThe Netherlands-based Tagworks Pharmaceuticals, a company that claims to be a pioneer of Click-to-Release chemistry to deliver effective and safer systemic therapies, announced on Thursday, June 22, that it has raised $65M (approximately €5...
15.09.2022ClavystBio launches to translate life sciences breakthroughs into health impactClavystBio will invest and work with partners to accelerate life sciences commercialisation in Singapore through three pillars: collaborate, venture and build. ClavystBio has committed US$220 million to date in investments to launch global ...
14.09.2021Lightstone Ventures Raises $375 Million Fund-
14.09.2021Lightstone Ventures : Raises $375 Million FundMENLO PARK, Calif. and BOSTON, Sept. 14, 2021 /PRNewswire/ -- Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact the...
14.09.2021After 3 big exits, Lightstone snags largest fund yet with $375M geared toward next biotechs, medtechs How to Optimize In Vitro and In Vivo Data Analysis and Data Management in Drug ResearchAfter seeing Ra Pharmaceuticals, Disarm Therapeutics and Tizona Therapeutics to exits last year, Lightstone Ventures is back with $375 million to plant a seed in early-stage biotech and medtech startups. Lightstone's raise comes amid a bann...
14.09.2021A not-so-secret, secret ingredient in Mailchimp’s new $12 billion valuationThis is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content How data can accelerate growth and innovation From Deloitte In a year when unicorn s...
14.09.2021Lightstone Ventures Raises $375M Fund to Invest in Early Stage Biotech and Medtech CompaniesWhat You Should Know: – Lightstone Ventures today announced the closing of Lightstone Ventures III with $375M in capital commitments, to invest in early-stage companies developing high-impact therapeutics and technologies. – The new fund wa...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In